175 related articles for article (PubMed ID: 35158900)
1. Clinical Value of Surveillance
Lim CH; Park SB; Kim HK; Choi YS; Kim J; Ahn YC; Ahn MJ; Choi JY
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158900
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of surveillance
Kim SJ; Hyun SH; Moon SH; Lee KS; Sun JM; Oh D; Ahn YC; Zo JI; Shim YM; Choi JY
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1850-1858. PubMed ID: 31222387
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of recurrence and follow-up using FDG-PET/CT for postoperative non-small-cell lung cancer patients.
Toba H; Kawakita N; Takashima M; Matsumoto D; Takizawa H; Otsuka H; Tangoku A
Gen Thorac Cardiovasc Surg; 2021 Feb; 69(2):311-317. PubMed ID: 32909168
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.
Toba H; Sakiyama S; Otsuka H; Kawakami Y; Takizawa H; Kenzaki K; Kondo K; Tangoku A
Interact Cardiovasc Thorac Surg; 2012 Nov; 15(5):859-64. PubMed ID: 22914804
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection.
Lee JW; Lee SM; Son MW; Lee MS
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):881-888. PubMed ID: 26611426
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection.
Lee YG; Han SW; Oh DY; Chie EK; Jang JY; Im SA; Kim TY; Kim SW; Ha SW; Bang YJ
BMC Cancer; 2011 May; 11():188. PubMed ID: 21599995
[TBL] [Abstract][Full Text] [Related]
9. The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy.
Lee JE; Hong SP; Ahn DH; Jeon TJ; Kang MK; Kwon CI; Ko KH; Hwang SG; Park PW; Rim KS
Yonsei Med J; 2011 Jan; 52(1):81-8. PubMed ID: 21155039
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis.
Goense L; van Rossum PS; Reitsma JB; Lam MG; Meijer GJ; van Vulpen M; Ruurda JP; van Hillegersberg R
J Nucl Med; 2015 Jul; 56(7):995-1002. PubMed ID: 25952733
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Value of FDG PET/CT in Surveillance after Curative Resection of Breast Cancer.
Lee H; Choi JY; Park YH; Lee JE; Kim SW; Nam SJ; Cho YS
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174111
[TBL] [Abstract][Full Text] [Related]
12. Primary Tumor ¹⁸F-FDG Avidity Affects the Performance of ¹⁸F-FDG PET/CT for Detecting Gastric Cancer Recurrence.
Kim SJ; Cho YS; Moon SH; Bae JM; Kim S; Choe YS; Kim BT; Lee KH
J Nucl Med; 2016 Apr; 57(4):544-50. PubMed ID: 26678615
[TBL] [Abstract][Full Text] [Related]
13. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
15. The role of ¹⁸F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making?
Bilici A; Ustaalioglu BB; Seker M; Kefeli U; Canpolat N; Tekinsoy B; Ozugur S; Gumus M
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):64-73. PubMed ID: 20838995
[TBL] [Abstract][Full Text] [Related]
16. Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
Pastis NJ; Greer TJ; Tanner NT; Wahlquist AE; Gordon LL; Sharma AK; Koch NC; Silvestri GA
Chest; 2014 Aug; 146(2):406-411. PubMed ID: 24577678
[TBL] [Abstract][Full Text] [Related]
17. Role of
Malik D; Sood A; Mittal BR; Basher RK; Bhattacharya A; Singh G
World J Nucl Med; 2019; 18(2):176-182. PubMed ID: 31040750
[TBL] [Abstract][Full Text] [Related]
18. Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence.
Sivarajah S; Isaac A; Cooper T; Zhang H; Puttagunta L; Abele J; Biron V; Harris J; Seikaly H; O' Connell DA
JAMA Otolaryngol Head Neck Surg; 2018 Nov; 144(11):1037-1043. PubMed ID: 30242338
[TBL] [Abstract][Full Text] [Related]
19. Nodal metabolic tumour volume on baseline
Alipour R; Bucknell N; Bressel M; Everitt S; MacManus M; Siva S; Hofman MS; Akhurst T; Hicks RJ; Iravani A
J Med Imaging Radiat Oncol; 2021 Oct; 65(6):748-754. PubMed ID: 34318603
[TBL] [Abstract][Full Text] [Related]
20. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
